Imetelstat
Geron Corporation
['mds']
6. #imerge: ipss low or intermediate-1 risk mds, r/r epo/esa, transfusion dependent (&gt;=4u rbc/8wks): imetelstat vs placebo - 8wk rate of ti higher with imetelstat
- rbc-ti rates: 8wk ti=40% and 24wk ti=28%
- favorable safety profile #asco23 7/7 
Practice changing 🗣 for community oncologists: w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own. COI: https://t.co/cJOjp0RvQE